UNDINE

Cohorts of SARS-CoV-2-infected subjects

This work package is dedicated to the establishment and monitoring of the clinical cohorts used in all the project’s experiments, covering multiple clinical phenotypes related to SARS-CoV-2 infection. All partners are involved in this WP1 and recruit patients, collect patient samples and curate clinical data for those cohorts. Based on data obtained from patients with COVID-19, the following clinical phenotypes have been defined:

1. COVID-19 Pneumonia: moderate, severe, or critical as per WHO guidelines.
2. Severe neurological forms of COVID-19 (neuro-COVID).
3. Multisystemic Inflammatory Syndrome of Children (MIS-C) or Adults (MIS-A) as per CDC definition.
4. Covid-toes, i.e. new onset chilblain-like perniosis.
5. Long COVID, defined as verified SARS-CoV-2 infection with prolonged symptoms/signs (>12 weeks), not be readily explained by a severe acute COVID-19 disease.
6. Asymptomatic infected individuals.
7. Resistant individuals: documented high exposure to SARS-CoV-2 with negative PCR and absent anti-SARS-CoV-2-specific antibodies.
8. Vaccine breakthrough infection: detection of SARS-CoV-2 RNA or antigen in a respiratory specimen collected from a person ≥14 days after all recommended doses of a COVID-19 vaccine.
9. Patients with defined Inborn Errors of Immunity (IEI), infected with SARS-CoV-2 and showing any of the above phenotypes.

For the clinical and biological data and material collection, DTAs and MTAs are in place. We classify all patients with a given phenotype as described above and collect available biological material, including plasma/serum, DNA, blood, PAXRNA, and PBMCs.